KIF18A Indication Prioritization Report: Oncology and Aging-Related Diseases

Executive Summary

• KIF18A (Kinesin Family Member 18A) is a microtubule-depolymerizing kinesin selectively required by chromosomally unstable (CIN) cancer cells but dispensable in normal diploid cells, creating a unique therapeutic window for CIN-selective anti-cancer therapy.
• We evaluated 13 indications across oncology (11 indications) and aging-related diseases (2 indications) using a multi-dimensional scoring framework integrating PandaOmics target-disease rankings, differential expression meta-analysis across 30 diseases, CIN prevalence data, clinical validation status, unmet medical need, and literature evidence.
• High-grade serous ovarian cancer (HGSOC) ranks as the top-priority indication (composite score: 9.2/10), supported by ~100% CIN prevalence, FDA Fast Track designations for two KIF18A inhibitors, and emerging clinical responses (3 partial responses in 17 evaluable ovarian cancer patients with VLS-1488).
• Triple-negative/basal-like breast cancer (score: 8.5/10) and CIN-high colorectal cancer (score: 7.8/10) represent the strongest expansion indications, with the highest KIF18A overexpression (logFC = 0.611 for basal-like breast cancer) and preclinical immunotherapy synergy data, respectively.
• Aging-related applications remain exploratory: KIF18A is not a classical aging target (Hallmarks of Aging count = 0), though genetic evidence links maternal KIF18A variants to age-related oocyte aneuploidy. Direct therapeutic development for aging indications is not currently supported.

Introduction

KIF18A Biology and Mechanism of Action

KIF18A (Kinesin Family Member 18A; NCBI Gene ID: 81930; UniProt: Q8NI77; Chromosome 11p14.1) is a kinesin-8 family motor protein that plays a critical role in mitotic chromosome alignment and congression. As a plus-end-directed microtubule motor with depolymerizing activity, KIF18A dampens kinetochore-microtubule dynamics during mitosis, enabling proper chromosome alignment at the metaphase plate. It operates in cooperation with CENP-E downstream of CENP-C and coordinates chromosome congression with cytokinesis.

The target is classified as Tbio (biologically validated target with no approved drugs), with a safety score of 1.0 and novelty score of 1.0 in the PandaOmics platform. KIF18A has 9 incoming, 9 outgoing, and 9 undirected protein-protein interactions, and no approved small molecules or antibodies currently target it.

CIN-Selective Therapeutic Paradigm

The central biological insight driving KIF18A drug development is its selective essentiality in chromosomally unstable (CIN) cancer cells. CIN tumors — characterized by ongoing chromosome mis-segregation, whole-genome doubling, and aneuploidy — exhibit elevated rates of kinetochore-microtubule attachment errors. These cells depend on KIF18A to dampen excessive microtubule dynamics and achieve viable chromosome alignment. When KIF18A is inhibited, CIN cells experience catastrophic mitotic failure (persistent spindle assembly checkpoint activation, multipolar spindles, and apoptosis), while normal diploid cells compensate through alternative alignment mechanisms. This creates a favorable therapeutic window with tumor selectivity distinct from conventional anti-mitotic agents.

Rationale for Indication Prioritization

With a KIF18A inhibitor compound originally indicated for solid tumors, this analysis seeks to systematically prioritize indications across oncology and aging-related diseases by integrating:

1. CIN prevalence by tumor type (the primary determinant of KIF18A sensitivity)
2. Differential gene expression (PandaOmics meta-analysis across 30 diseases)
3. PandaOmics target-disease scoring (50 indications ranked)
4. Clinical validation status and competitive landscape
5. Unmet medical need assessment
6. Literature and mechanistic evidence
7. Aging relevance (aging clock analysis, hallmarks of aging, longevity databases)

Methodology

PandaOmics Indication Scoring and Target Ranking

KIF18A was evaluated across 50 disease indications in the PandaOmics platform, generating multi-dimensional target-disease scores including relevance, expression, network, inference, pathway, PPI, community (matrixfact, hetewalk), LLM confidence, LLM commercial tractability, and LLM mechanism clarity scores. The top-ranked specific oncology indications include breast cancer (rank 3), hepatocellular carcinoma (rank 4), colorectal cancer (rank 5), and glioblastoma multiforme (rank 10).

Multi-Omics Expression Analysis

Differential expression of KIF18A was assessed via PandaOmics meta-analysis integrating multiple GEO datasets across 30 diseases and hundreds of individual experiments. Combined logFC values with associated p-values were extracted for each disease, representing meta-analyzed expression changes between disease and normal tissue.

Longevity-Lobster Dual-Purpose Target Analysis

KIF18A was assessed in the longevity-lobster platform for dual-purpose (oncology + aging) target potential. KIF18A appears as a disease target for breast cancer (rank 189, Phase II status) and ovarian cancer (rank 172, Phase II status).

Aging Clock and Hallmarks of Aging Analysis

KIF18A presence was evaluated across aging clocks (AltumAge methylation 2022, PASTA transcriptomics 2025, ZhangBLUP methylation 2019, Mammalian Life History clock 2024), geroprotector databases, GenAge, and ClinicalTrials.gov aging studies. Hallmarks of Aging (HOA) count was assessed.

Literature Review

Systematic PubMed literature search across 18 queries yielded ~80 unique publications spanning KIF18A biology, CIN selectivity, cancer-type-specific evidence, inhibitor development, and aging relevance.

Multi-Dimensional Composite Scoring Model

A composite score (0–10 scale) was generated for each indication incorporating: - CIN prevalence (weighted highest, as the primary mechanistic determinant) - Expression logFC (PandaOmics meta-analysis) - Clinical validation level - FDA regulatory engagement (Fast Track designations) - PandaOmics indication rank - Unmet medical need - Literature support strength - Aging relevance link

KIF18A Target Profile

Gene and Protein Overview

Mechanism of CIN-Selective Lethality

The mechanism by which KIF18A inhibition selectively kills CIN cancer cells has been elucidated through multiple landmark studies:

1. Chromosome alignment dependency (Marquis et al., 2021; Nat Commun): CIN cells specifically require KIF18A for proliferation; diploid cells do not.
2. Microtubule dynamics control (Fonseca et al., 2026; bioRxiv): KIF18A maintains kinetochore-microtubule attachments in CIN cells by limiting microtubule polymerization.
3. APC/C vulnerability (Gliech et al., 2024; EMBO J): Weakened APC/C activity at mitotic exit — common in CIN cancers — drives vulnerability to KIF18A inhibition.
4. Innate immune activation (Liu et al., 2025; Cell Death Discov): KIF18A inhibition in CIN tumors generates micronuclei that activate the cGAS-STING pathway, triggering antitumor immunity and enhancing PD-1 blockade.
5. Structural druggability (Schutt et al., 2024; Front Mol Biosci): The KIF18A alpha-4 helix provides a specific, druggable therapeutic target for CIN tumor cells.

Clinical Development Landscape

All three clinical programs are focused on HGSOC as the lead indication, reflecting the strong biological rationale of near-universal CIN prevalence in this tumor type.

Indication Prioritization Results

Multi-Dimensional Scoring Overview

Indication Prioritization Heatmap Figure 1. Multi-dimensional indication prioritization heatmap for KIF18A. Rows represent disease indications; columns show scoring dimensions including CIN prevalence, expression logFC, clinical validation, unmet need, literature support, and aging link. Color intensity reflects relative scoring on a normalized scale.

Composite Scores Figure 2. Composite prioritization scores across all 13 evaluated indications. Oncology indications shown in red; aging-related indications in purple. Scores range from 3.5 to 9.2 on a 10-point scale.

CIN vs Score Figure 3. CIN prevalence vs. composite prioritization score. Bubble size is proportional to the composite score. The strong positive correlation between CIN prevalence and composite score reflects the mechanistic basis of KIF18A-selective lethality.

Tiered Indication Ranking

The 13 evaluated indications are organized into four tiers based on composite scores, clinical readiness, and strategic value.

Tier 1 — Highest Priority (Score ≥ 8.0)

*HGSOC-specific expression data not available as a separate category in PandaOmics; ovarian cancer broadly ranked 22.

HGSOC (Score: 9.2/10): The premier indication for KIF18A inhibition. HGSOC has near-universal chromosomal instability (~100% CIN prevalence), rendering essentially all patients potential responders. Clinical proof-of-concept is emerging with VLS-1488 showing 3 partial responses in 17 evaluable ovarian cancer patients at ASCO 2025, with 7/17 patients showing tumor reduction. Two FDA Fast Track designations (VLS-1488 and sovilnesib) for platinum-resistant HGSOC underscore regulatory alignment. The unmet need is very high, particularly in platinum-resistant disease where median overall survival is <12 months with current therapies.

Breast Cancer — TNBC/Basal-like (Score: 8.5/10): The strongest expression signal across all cancers analyzed (logFC = 0.611 for basal-like breast carcinoma, p = 4.77 × 10⁻¹⁹). TNBC exhibits ~80% CIN prevalence, and CIN-high breast cancers (especially basal-like) were among the most sensitive lines to KIF18A inhibition in the Amgen AMG 650 screen. PandaOmics ranks breast cancer 3rd among all KIF18A indications with high relevance (0.888), inference (0.840), and LLM confidence (0.924) scores. KIF18A overexpression correlates with poor prognosis, higher tumor grade, and visceral metastasis in breast cancer.

Tier 2 — High Priority (Score 6.5–7.9)

Colorectal Cancer — CIN-high (Score: 7.8/10): A strategically differentiated indication due to preclinical evidence that KIF18A inhibition triggers antitumor immunity via cGAS-STING activation and enhances PD-1 blockade efficacy in CIN-phenotype CRC (Liu et al., 2025; Cell Death Discov). CRC has 65–85% CIN prevalence depending on subtype (CIN-high vs. MSI), significant KIF18A overexpression (logFC = 0.405, p = 3.44 × 10⁻⁵²), and PandaOmics rank of 5 with strong network (0.812), PPI (0.952), pathway (0.706), and transcriptomics (0.717) scores. The immunotherapy combination opportunity provides a compelling differentiation strategy.

Hepatocellular Carcinoma (Score: 7.2/10): Ranked 4th overall in PandaOmics with the highest network (0.935), PPI (0.935), community/matrixfact (0.894), and pathway (0.786) scores among oncology indications. HCC shows robust KIF18A overexpression (logFC = 0.520, p = 7.08 × 10⁻⁷¹) and 60–70% CIN prevalence. Multiple functional studies confirm KIF18A promotes HCC proliferation, invasion, and metastasis through PI3K/Akt, EMT, and 5-LOX/arachidonic acid pathways.

NSCLC (Score: 6.8/10): High CIN prevalence (60–75%), PandaOmics rank 24, and strong literature supporting KIF18A as a prognostic biomarker in lung adenocarcinoma. Functional validation shows KIF18A knockdown inhibits proliferation, migration, and invasion in lung cancer models.

Gastric Cancer (Score: 6.5/10): The CIN molecular subtype (~50% of gastric cancers) shows significant KIF18A overexpression (logFC = 0.493, p = 4.6 × 10⁻⁸⁶, the most statistically significant result across all diseases). Strong expression signal across 19 individual datasets.

Tier 3 — Moderate Priority (Score 4.5–6.4)

Osteosarcoma/Ewing Sarcoma (Score: 6.0/10): Notable for very high CIN prevalence (70–90%), validated KIF18A inhibitor efficacy in preclinical models (Yan et al., 2026: KIF18A inhibitor prevents CIN osteosarcoma growth by activating spindle assembly checkpoint), and testing in the PIVOT program with AMG 650. Ewing sarcoma shows significant KIF18A upregulation (logFC = 0.371, p = 4.07 × 10⁻¹⁰). The very high unmet need in pediatric/adolescent sarcomas and limited literature evidence position this as a promising but less validated opportunity.

Glioblastoma (Score: 5.2/10): Despite very high unmet need and PandaOmics rank 10 with strong network (0.841), PPI (0.970), and pathway (0.647) scores, moderate CIN prevalence (40–60%) and blood-brain barrier penetration challenges temper the overall score. KIF18A has been validated as a glioma prognostic biomarker correlating with immune infiltration and tumor grade.

Tier 4 — Aging-Related / Exploratory (Score < 4.5)

Age-related Oocyte Aneuploidy (Score: 4.5/10): The strongest KIF18A-aging connection. Biswas et al. (2024; PNAS) demonstrated that maternal genetic variants in KIF18A motor domains prematurely increase egg aneuploidy, directly linking KIF18A function to reproductive aging. PandaOmics ranks infertility 8th among KIF18A indications. However, no therapeutic development path for a KIF18A inhibitor in this context has been established — KIF18A inhibition would likely worsen, not improve, oocyte quality.

Age-related Neurodegeneration (Score: 3.5/10): An indirect and speculative connection. KIF18A shows modest upregulation in Alzheimer’s disease (logFC = 0.121, p = 0.01) across a meta-analysis of 21 datasets. The theoretical link is through the aneuploidy → cellular senescence → neurodegeneration axis. This indication is not actionable for drug development at present.

Disease-Specific Expression Profile

Expression Chart Figure 4. KIF18A differential expression across cancer types (PandaOmics meta-analysis, log₂ fold-change disease vs. normal). KIF18A is significantly upregulated in multiple solid tumors, with the strongest overexpression in basal-like breast carcinoma (logFC = 0.611), breast tumor luminal subtypes (logFC = 0.557), and hepatocellular carcinoma (logFC = 0.520). Notable downregulation is observed in azoospermia (logFC = −0.356), consistent with KIF18A’s known role in spermatogenesis.

Top KIF18A-Overexpressing Cancers (Combined Meta-Analysis logFC)

Downregulated Diseases

The downregulation in azoospermia is consistent with KIF18A’s essential role in spermatogenesis and meiotic chromosome segregation. Downregulation in hematologic malignancies (CLL, Hodgkin’s) suggests KIF18A inhibition may not be appropriate for these cancer types.

PandaOmics Omics Analysis

Radar Chart Figure 5. PandaOmics multi-omics scores for KIF18A across key oncology indications. Axes represent Expression, Network, Inference, Pathways, Community (matrixfact/hetewalk), LLM Confidence, and LLM Mechanism Clarity scores. Hepatocellular carcinoma and colorectal cancer show the most balanced high-scoring profiles across all omics dimensions, while breast cancer excels in relevance and inference scores.

Key PandaOmics Scores by Indication

Notably, lung cancer (rank 13 in PandaOmics; NSCLC specifically ranked 24) achieves the highest PPI score (0.978), network score (0.892), and relevance score (0.895) among individual indications, though its overall composite score is moderated by lower clinical validation evidence specific to KIF18A inhibitor trials.

Aging Relevance Assessment

KIF18A Is NOT a Classical Aging Target

A thorough assessment of KIF18A across aging-specific databases reveals limited direct aging relevance:

Primary Aging Connection: Reproductive Aging

The strongest KIF18A-aging link is through oocyte aneuploidy and reproductive aging:

• Biswas et al. (2024; PNAS): Maternal genetic variants in KIF18A motor domains prematurely increase egg aneuploidy, providing direct genetic evidence that KIF18A function declines with maternal age, contributing to the exponential rise in aneuploid conceptions after age 35.
• Mihajlovic et al. (2023; EMBO Rep): Spindle assembly checkpoint insensitivity allows meiosis-II despite chromosomal defects in aged eggs, with KIF18A part of the machinery that becomes less efficient with age.
• Ha et al. (2026; Hum Reprod Update): Review identifying KIF18A among key maternal genetic variants associated with aneuploid conception.

Important note: A KIF18A inhibitor would be contraindicated for reproductive aging, as KIF18A function is protective against oocyte aneuploidy. The aging relevance is mechanistic/biological rather than therapeutic.

Secondary Aging Connection: Aneuploidy-Senescence Axis

An indirect pathway connects KIF18A to aging through the aneuploidy → cellular senescence cascade:

• Aneuploidy is a known driver of cellular senescence (Cohen-Sharir et al., 2021; Nature)
• KIF18A dysfunction promotes aneuploidy in dividing cells
• Cellular senescence is a recognized hallmark of aging
• KIF18A shows modest upregulation in Alzheimer’s disease (logFC = 0.121, p = 0.01)

Conclusion: Aging applications for a KIF18A inhibitor are exploratory and speculative at this stage. The target’s primary value lies in oncology, specifically CIN-selective cancer therapy. Monitoring of aging-relevant data (particularly reproductive biology and senescence biology) is warranted, but active therapeutic development for aging indications is not supported by current evidence.

Competitive Landscape

Current KIF18A Inhibitor Programs

The KIF18A inhibitor landscape is concentrated among three programs, all converging on HGSOC as the lead indication:

1. VLS-1488 (Volastra Therapeutics) - Most advanced clinical program - Phase I/II for advanced solid tumors (NCT05902988) - FDA Fast Track for platinum-resistant HGSOC (October 2024) - ASCO 2025 data: 52 patients enrolled, no dose-limiting toxicities, 7/17 evaluable ovarian cancer patients showed tumor reduction, 3 confirmed partial responses - Dose expansion ongoing

2. Sovilnesib / AMG 650 (Volastra Therapeutics / Amgen) - Originally developed by Amgen as a chemical probe (AMG 650); licensed to Volastra in 2023 - Phase I for ovarian cancer - FDA Fast Track for HGSOC - Foundational preclinical data published in Nature Cancer (Payton et al., 2024)

3. ACNT-2 (Accent Therapeutics) - Phase I/II for locally advanced/metastatic solid tumors (NCT06799065) - First patient dosed April 2025 - FDA Fast Track designation - Structurally distinct KIF18A inhibitor

Preclinical Tools and Academic Compounds

Emerging Vulnerabilities Expanding KIF18A Opportunity

• JAK1 loss creates G2-M cell-cycle defects vulnerable to KIF18A inhibition, potentially expanding the patient population beyond CIN-defined tumors (Kelley et al., 2026; Cancer Res).
• KIF18A + ICI combinations in CIN-high CRC represent a differentiation strategy through cGAS-STING-mediated immune activation.

Strategic Recommendations

1. HGSOC as Lead Indication — Follow Clinical Data

• Rationale: Near-universal CIN prevalence (~100%), emerging clinical proof-of-concept (VLS-1488 partial responses), two FDA Fast Track designations, very high unmet need in platinum-resistant disease.
• Action: Advance clinical development with HGSOC as the registration-enabling indication. Monitor VLS-1488 dose expansion data and Accent ACNT-2 readouts for competitive positioning.

2. TNBC/Basal-like Breast Cancer as First Expansion — Highest Expression Signal

• Rationale: Highest KIF18A overexpression of any cancer type (logFC = 0.611), ~80% CIN in TNBC, PandaOmics rank 3, strong prognostic biomarker literature, and high unmet need particularly in later-line metastatic TNBC.
• Action: Initiate CIN-biomarker-stratified clinical trial in TNBC. Consider combination with immune checkpoint inhibitors given the cGAS-STING activation mechanism.

3. CRC CIN-high + Immune Checkpoint Inhibitor Combination — Differentiation Strategy

• Rationale: Preclinical evidence for synergy between KIF18A inhibition and PD-1 blockade via cGAS-STING pathway activation in CIN-phenotype CRC. This is a unique mechanistic opportunity to convert CIN-high/MSS colorectal cancers (which are traditionally ICI-resistant) into ICI-responsive tumors.
• Action: Design combination trial (KIF18A inhibitor + anti-PD-1) in CIN-high/MSS CRC with CIN biomarker selection.

4. HCC and NSCLC as Second-Wave Expansions

• Rationale: Both indications show high CIN prevalence (60–75%), strong KIF18A overexpression (HCC logFC = 0.520), robust PandaOmics scores, and high unmet need. HCC ranks 4th and lung cancer 13th in PandaOmics.
• Action: Conduct basket trial inclusion of HCC and NSCLC cohorts in later-stage clinical development. HCC may benefit from combination with anti-PD-L1 agents (current standard of care).

5. Osteosarcoma/Ewing Sarcoma — Pediatric/Rare Tumor Opportunity

• Rationale: Very high CIN prevalence (70–90%), preclinical KIF18A inhibitor efficacy demonstrated, very high unmet need in pediatric sarcomas with limited treatment options beyond surgery and chemotherapy.
• Action: Explore pediatric development pathway with regulatory incentives (orphan drug designation, Rare Pediatric Disease designation). The PIVOT program already tested AMG 650 preclinically in sarcoma models.

6. Aging Indications — Monitor Only

• Rationale: KIF18A is not a classical aging target (HOA count = 0), not present in geroprotector or GenAge databases, and the primary aging link (reproductive aging/oocyte aneuploidy) would require KIF18A activation, not inhibition.
• Action: No active therapeutic development for aging indications. Monitor emerging literature on the aneuploidy-senescence axis and KIF18A’s role in aging clocks. The dual-purpose oncology-aging narrative does not hold for a KIF18A inhibitor compound.

Conclusions

This comprehensive indication prioritization analysis of KIF18A for a small-molecule inhibitor compound identifies a clear development path anchored in the CIN-selective lethality paradigm:

1. HGSOC is the unambiguous lead indication (composite score: 9.2/10), combining near-universal CIN prevalence, emerging clinical validation, FDA regulatory support, and very high unmet medical need. All three competing clinical programs are focused here, validating the indication choice.

2. TNBC/basal-like breast cancer represents the strongest expansion opportunity (score: 8.5/10), driven by the highest KIF18A overexpression across all cancers and high CIN prevalence.

3. CIN-high colorectal cancer offers a unique differentiation opportunity (score: 7.8/10) through combination with immune checkpoint inhibitors, leveraging KIF18A inhibition’s ability to activate antitumor immunity via cGAS-STING signaling.

4. Second-wave indications (HCC, NSCLC, gastric cancer, osteosarcoma) provide expansion potential with established CIN prevalence and expression data but require further preclinical and clinical validation.

5. Aging-related indications are not actionable for a KIF18A inhibitor compound. While KIF18A has genuine biological connections to aging (oocyte aneuploidy, aging clock presence), these connections do not translate into a therapeutic rationale for KIF18A inhibition in aging diseases.

The critical success factor for KIF18A inhibitor development across all oncology indications is patient selection based on CIN biomarkers (whole-genome doubling, CIN gene signatures, or ploidy assessment). Indications with higher CIN prevalence consistently score higher, reinforcing that the biological mechanism — not the tissue of origin — is the primary determinant of therapeutic potential.

References

1. Truong JQ, Galper T, Holien JK. KIF18A inhibition and its rising role in cancer therapy trials: from bench to bedside. Expert Opin Investig Drugs. 2026 Jan. doi:10.1080/13543784.2026.2616752. PMID: 41543111.

2. Nair J, Huang TT, Lynes M et al. The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells. Cells. 2025 Nov 26. doi:10.3390/cells14231863. PMID: 41369352.

3. Payton M, Belmontes B, Hanestad K et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nat Cancer. 2024 Jan. doi:10.1038/s43018-023-00699-5. PMID: 38151625.

4. Marquis C, Fonseca CL, Queen KA et al. Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nat Commun. 2021 Feb 22. doi:10.1038/s41467-021-21447-2. PMID: 33619254.

5. Fonseca C, Fisher K, Wagner E et al. KIF18A Maintains Kinetochore-Microtubule Attachments in CIN Cells by Limiting Microtubule Polymerization. bioRxiv. 2026 Apr 17. doi:10.64898/2026.04.15.718686. PMID: 42039568.

6. Phillips AF, Zhang R, Jaffe M et al. Targeting chromosomally unstable tumors with a selective KIF18A inhibitor. Nat Commun. 2025 Jan 2. doi:10.1038/s41467-024-55300-z. PMID: 39747049.

7. Liu G, Zhang Y, Cao Z et al. Targeting KIF18A triggers antitumor immunity and enhances efficiency of PD-1 blockade in colorectal cancer with chromosomal instability phenotype. Cell Death Discov. 2025 Apr 2. doi:10.1038/s41420-025-02437-5. PMID: 40175357.

8. Gliech CR, Yeow ZY, Tapias-Gomez D et al. Weakened APC/C activity at mitotic exit drives cancer vulnerability to KIF18A inhibition. EMBO J. 2024 Mar. doi:10.1038/s44318-024-00031-6. PMID: 38279026.

9. Schutt KL, Queen KA, Fisher K et al. Identification of the KIF18A alpha-4 helix as a therapeutic target for chromosomally unstable tumor cells. Front Mol Biosci. 2024. doi:10.3389/fmolb.2024.1328077. PMID: 38410188.

10. Chen Q, Le X, Li Q et al. Exploration of inhibitors targeting KIF18A with ploidy-specific lethality. Drug Discov Today. 2024 Oct. doi:10.1016/j.drudis.2024.104142. PMID: 39168405.

11. Mohd Amin AS, Eastwood S, Pilcher C et al. KIF18A inhibition: the next big player in the search for cancer therapeutics. Cancer Metastasis Rev. 2024 Nov 24. doi:10.1007/s10555-024-10225-3. PMID: 39580563.

12. Biswas L, Tyc KM, Aboelenain M et al. Maternal genetic variants in kinesin motor domains prematurely increase egg aneuploidy. Proc Natl Acad Sci U S A. 2024 Nov 5. doi:10.1073/pnas.2414963121. PMID: 39475646.

13. Zhang C, Tu P, Jia X et al. Design, Biological Characterization, and Discovery of Novel Cyclohexenyl Derivatives as Kinesin KIF18A Inhibitors for the Treatment of Ovarian Cancer. ACS Med Chem Lett. 2024 Oct 10. doi:10.1021/acsmedchemlett.4c00383. PMID: 39411524.

14. Sparling BA, Lee H, Zablocki MM et al. Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement. ACS Med Chem Lett. 2025 Nov 13. doi:10.1021/acsmedchemlett.5c00512. PMID: 41257005.

15. Hemida AS, Shabaan MI, Taha MA et al. Impact of immunohistochemical expression of kinesin family member 18A (Kif18A) and β-catenin in infiltrating breast carcinoma of no special type. World J Surg Oncol. 2024 Jan 10. doi:10.1186/s12957-023-03276-3. PMID: 38195458.

16. Nagahara M, Nishida N, Iwatsuki M et al. Kinesin 18A expression: clinical relevance to colorectal cancer progression. Int J Cancer. 2011 Dec 1. doi:10.1002/ijc.25916. PMID: 21213216.

17. Zhu H, Xu W, Zhang H et al. Targeted deletion of Kif18a protects from colitis-associated colorectal (CAC) tumors in mice through impairing Akt phosphorylation. Biochem Biophys Res Commun. 2013 Aug 16. doi:10.1016/j.bbrc.2013.07.032. PMID: 23872115.

18. Ren J, Yao X, Yang M et al. Kinesin Family Member-18A (KIF18A) Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma. Dig Dis Sci. 2024 Apr. doi:10.1007/s10620-024-08321-z. PMID: 38446308.

19. Wang Y, Cai T, Chen Y et al. KIF18A induces the EMT process of hepatoma cells through the 5-LOX-dependent arachidonic acid pathway. PLoS One. 2025. doi:10.1371/journal.pone.0333385. PMID: 41082523.

20. Li X, Liu M, Zhang Z et al. High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. Thorac Cancer. 2019 May. doi:10.1111/1759-7714.13051. PMID: 30907518.

21. Yan Q, Zhang Y, Wang P et al. KIF18A inhibitor prevents chromosomally unstable osteosarcoma growth by activating spindle assembly checkpoint. Cancer Biol Ther. 2026 Dec 31. doi:10.1080/15384047.2026.2689181. PMID: 42328720.

22. Gu Z, Zhang S, Hu X et al. Deciphering the Role of KIF18A in Osteosarcoma Progression: An Integrative Analysis and Experimental Validation. Front Biosci (Landmark Ed). 2025 Oct 29. doi:10.31083/FBL44663. PMID: 41198558.

23. Kelley VM, Baro M, Gasperi WE et al. Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition. Cancer Res. 2026 May 4. doi:10.1158/0008-5472.CAN-25-1423. PMID: 41591363.

24. Liu T, Yang K, Chen J et al. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Biomolecules. 2023 Feb 8. doi:10.3390/biom13020326. PMID: 36830695.

25. Tamayo NA, Bourbeau MP, Allen JR et al. Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe. J Med Chem. 2022 Mar 24. doi:10.1021/acs.jmedchem.1c02030. PMID: 35286090.

26. Cohen-Sharir Y, McFarland JM, Abdusamad M et al. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021 Feb. doi:10.1038/s41586-020-03114-6. PMID: 33505028.

27. Mihajlović AI, Byers C, Reinholdt L et al. Spindle assembly checkpoint insensitivity allows meiosis-II despite chromosomal defects in aged eggs. EMBO Rep. 2023 Nov 6. doi:10.15252/embr.202357227. PMID: 37795949.

28. Ha S, Liu W, Yuan P et al. Maternal genetic variants associated with aneuploid conception: a narrative review. Hum Reprod Update. 2026 May 13. doi:10.1093/humupd/dmag012. PMID: 42124334.

29. Li TF, Zeng HJ, Shan Z et al. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer. Cancer Cell Int. 2020. doi:10.1186/s12935-020-01191-1. PMID: 32322170.

30. Liu Y, Sun M, Zhang B et al. KIF18A improves migration and invasion of colorectal cancer (CRC) cells through inhibiting PTEN signaling. Aging (Albany NY). 2023 Sep 13. doi:10.18632/aging.205027. PMID: 37708299.

31. Miao J, Hara M, Su KC et al. KIF18A promotes chromosome congression in cooperation with CENP-E downstream of CENP-C. Cell Rep. 2025 Nov 25. doi:10.1016/j.celrep.2025.116515. PMID: 41218610.

32. Nan K, Zhang L, Zou Y et al. Integrated Profiling Delineated KIF18A as a Significant Biomarker Associated with Both Prognostic Outcomes and Immune Response in Pancreatic Cancer. Immunotargets Ther. 2025. doi:10.2147/ITT.S497284. PMID: 40040635.

33. Tanasuka P, Thongpon P, Chomwong S et al. Suppression of kinesin family member-18A diminishes progression and induces apoptotic cell death of gemcitabine-resistant cholangiocarcinoma cells by modulating PI3K/Akt/mTOR and NF-κB pathways. PLoS One. 2025. doi:10.1371/journal.pone.0334147. PMID: 41091720.

34. Wang M, Lukanovic D, Barra F et al. KIF18A and CDK1 as combined therapeutic targets in cervical and endometrial carcinomas. Transl Cancer Res. 2024 Dec 31. doi:10.21037/tcr-24-1831. PMID: 39816554.

35. Lv Y, Feng G, Yang L et al. Differential whole-genome doubling based signatures for improvement on clinical outcomes and drug response in patients with breast cancer. Heliyon. 2024 Apr 15. doi:10.1016/j.heliyon.2024.e28586. PMID: 38576569.

36. Nesbit C, Martin W, Czechanski A et al. Anapc5 and Anapc7 as genetic modifiers of KIF18A function in fertility and mitotic progression. Sci Rep. 2025 Jul 2. doi:10.1038/s41598-025-08766-w. PMID: 40596695.

37. Walczak CE. Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future. Cytoskeleton (Hoboken). 2026 Jul 28. doi:10.1002/cm.70179. PMID: 42517274.

38. Schiewek J, Schumacher U, Lange T et al. Clinical relevance of cytoskeleton associated proteins for ovarian cancer. J Cancer Res Clin Oncol. 2018 Nov. doi:10.1007/s00432-018-2710-9. PMID: 30094535.